Clinical trial
Gemcitabine and Docetaxel in Treating Patients With Recurrent Stage III or Stage…
NCT00278460 · Wake Forest University Health Sciences, Other · Completed
Key facts
| NCT number | NCT00278460 |
|---|---|
| Title | Gemcitabine and Docetaxel in Treating Patients With Recurrent Stage III or Stage IV Non-Small Cell Lung Cancer |
| Official title | A Phase II Study of Taxotere and Gemcitabine for Stages III-B and IV Non-Small Cell Lung Cancer |
| Lead sponsor | Wake Forest University Health Sciences, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | docetaxel, gemcitabine hydrochloride |
| Enrollment | 49 |
| Start date | Nov 1, 2000 |
| Primary completion | Feb 1, 2006 |
| Completion | Sep 1, 2007 |
| First posted | Jan 18, 2006 |
| Last update posted | Jan 19, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: